Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Davidson

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
The American Journal of Cardiology|March 13, 2001
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agentsM H Davidson
The American Journal of Clinical Nutrition|March 4, 2000
Efficacy of antiobesity therapiesM H Davidson
Drugs|March 29, 2001
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trustM H Davidson
Current Atherosclerosis Reports|December 21, 2000
Statin trials in progress: unanswered questionsM H Davidson
The American Journal of Medicine|June 6, 1994
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safetyM H Davidson
Journal of Cardiovascular Pharmacology and Therapeutics|October 5, 2001
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactionsM H Davidson
Regulatory Toxicology and Pharmacology : RTP|February 1, 1996
Food additive approvals: risks vs benefitsM H Davidson
Current Atherosclerosis Reports|December 21, 2000
Does differing metabolism by cytochrome p450 have clinical importance?M H Davidson
The American Journal of Cardiology|February 25, 1993
Antioxidants and lipid metabolism. Implications for the present and direction for the futureM H Davidson
The American Journal of Medicine|June 6, 1994
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacyC A Dujovne, M H Davidson
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
The American Journal of Cardiology|March 13, 2001
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agentsM H Davidson
The American Journal of Clinical Nutrition|March 4, 2000
Efficacy of antiobesity therapiesM H Davidson
Drugs|March 29, 2001
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trustM H Davidson
Current Atherosclerosis Reports|December 21, 2000
Statin trials in progress: unanswered questionsM H Davidson
The American Journal of Medicine|June 6, 1994
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safetyM H Davidson
Journal of Cardiovascular Pharmacology and Therapeutics|October 5, 2001
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactionsM H Davidson
Regulatory Toxicology and Pharmacology : RTP|February 1, 1996
Food additive approvals: risks vs benefitsM H Davidson
Current Atherosclerosis Reports|December 21, 2000
Does differing metabolism by cytochrome p450 have clinical importance?M H Davidson
The American Journal of Cardiology|February 25, 1993
Antioxidants and lipid metabolism. Implications for the present and direction for the futureM H Davidson
The American Journal of Medicine|June 6, 1994
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacyC A Dujovne, M H Davidson
Pageof 7